Health, London SUMMARY We investigated 24 hour growth hormone secretion by intermittent 20 minute blood sampling in 34 prepubertal patients with Turner's syndrome, aged 4-3-12-4 years. Growth hormone profiles were analysed by the PULSAR programme and results expressed as the sum of growth hormone pulse amplitudes. Six patients had abnormal growth hormone pulse frequencies. In the remaining 28, growth hormone pulse amplitudes declined significantly with increasing age, but there was no correlation between growth hormone pulse amplitudes and growth rates. Concentrations of insulin like growth factor-1 (IGF-1) rose with age but did not correlate with either growth rates or growth hormone secretion. Fifteen patients were given oxandrolone and 11 low dose ethinyl oestradiol. Both agents increased height velocity without increasing growth hormone secretion.
We conclude that the relation between growth hormone secretion and growth in Turner's syndrome is less certain than in normal children. End organ resistance is probably due to a skeletal dysplasia. Both oxandrolone and low dose ethinyl oestradiol improve the growth of girls with Turner's syndrome, but their mechanism of action remains uncertain.
Patients with Turner's syndrome are born short, grow slowly, and achieve a reduced adult stature.1 2 Although individual cases of growth hormone deficiency have been reported in Turner's syndrome,3 growth hormone responses to pharmacological stimuli are similar to those seen in normal short children.4 5 Endogenous growth hormone secretion is known to be pulsatile and may be assessed in children using intermittent blood sampling over 24 hours.6 In some children, considerable discrepancies have been noted between the growth hormone concentrations reached on such assessments and the results of pharmacological provocation tests.' Tall children produce more growth hormone over 24 hours than short children,8 and it appears to be growth hormone pulse amplitude that correlates with growth rate in otherwise normal children.9 The periodicity of growth hormone secretion is also relevant, abnormal patterns being associated with inadequate growth. 8 We sought to investigate the qualitative and quantitative aspects of growth hormone secretion in Turner's syndrome and to determine the effect of growth promoting agents. The anabolic steroid oxandrolone is known to increase height velocity in Turner's syndrome.10 11 Low dose ethinyl oestradiol increases height velocity in both the short'2 and long term. 13 The effects of these treatments on growth hormone secretion in Turner's syndrome is unknown.
Patients and methods
Thirty four patients aged 4-3 to 12-4 years (median 9-1) were studied. Karyotypes, performed by culture of peripheral lymphocytes, are shown in table 1 Growth hormone concentrations were measured by a solid phase immunoradiometric assay (Tandem R, Hybritech14), all specimens from one subject being analysed in a single batch. The lower limit of sensitivity of the assay was 0-5 mU/l. The intra-assay coefficients of variation were 10*6, 7-8, and 4-8% at 1-4, 7.1, and 26-4 mU/l respectively.
Computerised pulse analysis was performed using the PULSAR programme 5 modified for growth hormone.9 This generates a smoothed but variable baseline and defines pulses above that baseline, by taking into account the amplitude and duration of rises and the standard deviation of the assay. We have used simple arithmetric addition of the maximum amplitude of the defined pulses to generate the statistic 'sum of peak amplitudes'.
Plasma concentrations of IGF-1 were measured by radioimmunoassay.'6 The lower limit of sensitivity of the assay was 0-03 U/ml and the coefficients of variation were 11-0, 7-2, and 7-0% at 0-15, 0-47, and 0-94 U/ml respectively. Height was measured every three months by standard techniques using a Harpenden stadiometer. In order to account for varying height velocities at different ages, height velocity standard deviation scores (SDS) were calculated using normal data for Turner's syndrome2 by the formula: Oxandrolone increased IGF-1 as reported by others. I In conclusion, although growth hormone secretion declined with age in Turner's syndrome, the relation to growth is uncertain, and end organ resistance in the form of a skeletal dysplasia vrobably plays a major part in the growth failure.' The experience that higher doses of growth hormone are required to achieve the same response as normal children supports this view and is against decreased bioactivity of endogenous growth hormone. Long term growth hormone treatment in pharmacological doses may nevertheless improve height prognosis. The onset of growth failure in early life implies that such treatment should be commenced well within the first decade. Our results suggest that tests of growth hormone secretion may not be helpful in selection of patients for such treatment. Oxandrolone and ethinyl oestradiol remain effective modes of treatment in Turner's syndrome, though their mechanisms of action in growth promotion remain uncertain.
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